{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:24:49Z","timestamp":1740165889651,"version":"3.37.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T00:00:00Z","timestamp":1685145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T00:00:00Z","timestamp":1685145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"DOI":"10.1007\/s13730-023-00798-3","type":"journal-article","created":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T17:01:48Z","timestamp":1685206908000},"page":"53-58","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Relapse of minimal change disease following the third mRNA COVID-19 vaccination: a case report and literature review"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4116-0962","authenticated-orcid":false,"given":"Mariko","family":"Teragaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoka","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Takeoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Awaisshafig","family":"Fukumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohtaro","family":"Takami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirona","family":"Saita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachio","family":"Iwanari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroya","family":"Takeoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,27]]},"reference":[{"issue":"4","key":"798_CR1","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa2107058","volume":"385","author":"MG Thompson","year":"2021","unstructured":"Thompson MG, Burgess JL, Naleway AL, Tyner H, Yoon SK, Meece J, et al. Prevention and attenuation of Covid-19 with the BNT162b2 and mRNA-1273 vaccines. N Engl J Med. 2021;385(4):320\u20139.","journal-title":"N Engl J Med"},{"issue":"15","key":"798_CR2","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","volume":"385","author":"YM Bar-On","year":"2021","unstructured":"Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med. 2021;385(15):1393\u2013400.","journal-title":"N Engl J Med"},{"issue":"1","key":"798_CR3","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1053\/j.ajkd.2021.03.010","volume":"78","author":"L Lebedev","year":"2021","unstructured":"Lebedev L, Sapojnikov M, Wechsler A, Varadi-Levi R, Zamir D, Tobar A, et al. Minimal change disease Following the Pfizer-BioNTech COVID-19 vaccine. Am J Kidney Dis. 2021;78(1):142\u20135.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"798_CR4","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.kint.2021.09.002","volume":"100","author":"NL Li","year":"2021","unstructured":"Li NL, Coates PT, Rovin BH. COVID-19 vaccination followed by activation of glomerular diseases: does association equal causation? Kidney Int. 2021;100(5):959\u201365.","journal-title":"Kidney Int"},{"issue":"12","key":"798_CR5","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1016\/j.ekir.2021.09.008","volume":"6","author":"N Klomjit","year":"2021","unstructured":"Klomjit N, Alexander MP, Fervenza FC, Zoghby Z, Garg A, Hogan MC, et al. COVID-19 vaccination and glomerulonephritis. Kidney Int Rep. 2021;6(12):2969\u201378.","journal-title":"Kidney Int Rep"},{"issue":"9","key":"798_CR6","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1016\/j.ekir.2021.07.017","volume":"6","author":"F Salem","year":"2021","unstructured":"Salem F, Rein JL, Yu SMW, Abramson M, Cravedi P, Chung M. Report of three cases of minimal change disease following the second dose of mRNA SARS-CoV-2 COVID-19 vaccine. Kidney Int Rep. 2021;6(9):2523\u20134.","journal-title":"Kidney Int Rep"},{"issue":"3","key":"798_CR7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1053\/j.ajkd.2021.05.006","volume":"78","author":"H Komaba","year":"2021","unstructured":"Komaba H, Wada T, Fukagawa M. Relapse of minimal change disease following the Pfizer-BioNTech COVID-19 vaccine. Am J Kidney Dis. 2021;78(3):469\u201370.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"798_CR8","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.kint.2021.05.006","volume":"100","author":"N Schwotzer","year":"2021","unstructured":"Schwotzer N, Kissling S, Fakhouri F. Letter regarding \u201cMinimal change disease relapse following SARS-CoV-2 mRNA vaccine.\u201d Kidney Int. 2021;100(2):458\u20139.","journal-title":"Kidney Int"},{"issue":"4","key":"798_CR9","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s40620-021-01091-1","volume":"34","author":"N Mancianti","year":"2021","unstructured":"Mancianti N, Guarnieri A, Tripodi S, Salvo DP, Garosi G. Minimal change disease following vaccination for SARS-CoV-2. J Nephrol. 2021;34(4):1039\u201340.","journal-title":"J Nephrol"},{"issue":"2","key":"798_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.kint.2021.04.033","volume":"100","author":"D Kervella","year":"2021","unstructured":"Kervella D, Jacquemont L, Chapelet-Debout A, Deltombe C, Ville S. Minimal change disease relapse following SARS-CoV-2 mRNA vaccine. Kidney Int. 2021;100(2):457\u20138.","journal-title":"Kidney Int"},{"issue":"2","key":"798_CR11","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.kint.2021.06.005","volume":"100","author":"C Morlidge","year":"2021","unstructured":"Morlidge C, El-Kateb S, Jeevaratnam P, Thompson B. Relapse of minimal change disease following the AstraZeneca COVID-19 vaccine. Kidney Int. 2021;100(2):459.","journal-title":"Kidney Int"},{"issue":"4","key":"798_CR12","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s11255-021-02889-5","volume":"54","author":"G \u00d6zkan","year":"2022","unstructured":"\u00d6zkan G, Bayrak\u00e7\u0131 N, Karaba\u011f S, G\u00fczel E, Ulusoy S. Relapse of minimal change disease after inactivated SARS-CoV-2 vaccination: case report. Int Urol Nephrol. 2022;54(4):971\u20132.","journal-title":"Int Urol Nephrol"},{"issue":"8","key":"798_CR13","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1093\/ckj\/sfac134","volume":"15","author":"A Hummel","year":"2022","unstructured":"Hummel A, Oniszczuk J, Kervella D, Charbit M, Guerrot D, Testa A, et al. Idiopathic nephrotic syndrome relapse following COVID-19 vaccination: a series of 25 cases. Clin Kidney J. 2022;15(8):1574\u201382.","journal-title":"Clin Kidney J"},{"issue":"3","key":"798_CR14","doi-asserted-by":"publisher","first-page":"e244638","DOI":"10.1136\/bcr-2021-244638","volume":"15","author":"JL Hartley","year":"2022","unstructured":"Hartley JL, Bailey N, Sharma A, Shawki H. Nephrotic syndrome with minimal change disease after the Pfizer-BioNTech COVID-19 vaccine: two cases. BMJ Case Rep. 2022;15(3):e244638.","journal-title":"BMJ Case Rep"},{"issue":"1","key":"798_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.5414\/CNCS110924","volume":"10","author":"P Chandra","year":"2022","unstructured":"Chandra P, Roldao M, Drachenberg C, Santos P, Washida N, Clark A, et al. Minimal change disease and COVID-19 vaccination: four cases and review of literature. Clin Nephrol Case Stud. 2022;10(1):54\u201363.","journal-title":"Clin Nephrol Case Stud"},{"issue":"10","key":"798_CR16","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1093\/ckj\/sfab123","volume":"14","author":"AB Dirim","year":"2021","unstructured":"Dirim AB, Safak S, Andac B, Garayeva N, Demir E, Artan AS, et al. Minimal change disease following vaccination with CoronaVac. Clin Kidney J. 2021;14(10):2268\u20139.","journal-title":"Clin Kidney J"},{"issue":"12","key":"798_CR17","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1093\/ckj\/sfab155","volume":"14","author":"S Unver","year":"2021","unstructured":"Unver S, Haholu A, Yildirim S. Nephrotic syndrome and acute kidney injury following CoronaVac anti-SARS-CoV-2 vaccine. Clin Kidney J. 2021;14(12):2608\u201311.","journal-title":"Clin Kidney J"},{"issue":"2","key":"798_CR18","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.kint.2021.04.035","volume":"100","author":"VD D\u2019Agati","year":"2021","unstructured":"D\u2019Agati VD, Kudose S, Bomback AS, Adamidis A, Tartini A. Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine. Kidney Int. 2021;100(2):461\u20133.","journal-title":"Kidney Int"},{"issue":"2","key":"798_CR19","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1053\/j.ajkd.2021.05.003","volume":"78","author":"RJ Maas","year":"2021","unstructured":"Maas RJ, Gianotten S, van der Meijden WAG. An additional case of minimal change disease following the Pfizer-BioNTech COVID-19 vaccine. Am J Kidney Dis. 2021;78(2):312.","journal-title":"Am J Kidney Dis"},{"key":"798_CR20","doi-asserted-by":"publisher","first-page":"205435812110582","DOI":"10.1177\/20543581211058271","volume":"8","author":"J Hanna","year":"2021","unstructured":"Hanna J, Ingram A, Shao T. Minimal change disease after first dose of Pfizer-BioNTech COVID-19 vaccine: a case report and review of minimal change disease related to COVID-19 vaccine. Can J Kidney Health Dis. 2021;8:20543581211058270.","journal-title":"Can J Kidney Health Dis"},{"issue":"2","key":"798_CR21","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.kint.2021.06.004","volume":"100","author":"J Weijers","year":"2021","unstructured":"Weijers J, Alvarez C, Hermans MMH. Post-vaccinal minimal change disease. Kidney Int. 2021;100(2):459\u201361.","journal-title":"Kidney Int"},{"issue":"1","key":"798_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/medicina58010037","volume":"58","author":"S Marinaki","year":"2021","unstructured":"Marinaki S, Kolovou K, Liapis G, Skalioti C, Tsiakas S, Boletis I. De novo minimal change disease following vaccination with the Pfizer\/BioNTech SARS-CoV-2 vaccine in a living kidney donor. Medicina (Kaunas). 2021;58(1):37.","journal-title":"Medicina (Kaunas)"},{"issue":"12","key":"798_CR23","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1093\/ckj\/sfab156","volume":"14","author":"S Kobayashi","year":"2021","unstructured":"Kobayashi S, Fugo K, Yamazaki K, Terawaki H. Minimal change disease soon after Pfizer-BioNTech COVID-19 vaccination. Clin Kidney J. 2021;14(12):2606\u20137.","journal-title":"Clin Kidney J"},{"issue":"1","key":"798_CR24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/nep.13995","volume":"27","author":"K Baskaran","year":"2022","unstructured":"Baskaran K, Cohen AWS, Weerasinghe N, Vilayur E. Report of two cases of minimal change disease following vaccination for COVID-19. Nephrology (Carlton). 2022;27(1):111\u20132.","journal-title":"Nephrology (Carlton)"},{"issue":"10","key":"798_CR25","doi-asserted-by":"publisher","first-page":"e05003","DOI":"10.1002\/ccr3.5003","volume":"9","author":"M Abdulgayoom","year":"2021","unstructured":"Abdulgayoom M, Albuni MK, Abdelmahmuod E, Murshed K, Eldeeb Y. Minimal change nephrotic syndrome four days after the administration of Pfizer-BioNTech COVID-19 vaccine\u2014a new side effect or coincidence? Clin Case Rep. 2021;9(10):e05003.","journal-title":"Clin Case Rep"},{"issue":"2","key":"798_CR26","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.kint.2021.05.007","volume":"100","author":"A Holzworth","year":"2021","unstructured":"Holzworth A, Couchot P, Cruz-Knight W, Brucculeri M. Minimal change disease following the Moderna mRNA-1273 SARS-CoV-2 vaccine. Kidney Int. 2021;100(2):463\u20134.","journal-title":"Kidney Int"},{"issue":"1","key":"798_CR27","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1186\/s12882-021-02583-9","volume":"22","author":"S Thappy","year":"2021","unstructured":"Thappy S, Thalappil SR, Abbarh S, Al-Mashdali A, Akhtar M, Alkadi MM. Minimal change disease following the Moderna COVID-19 vaccine: first case report. BMC Nephrol. 2021;22(1):376.","journal-title":"BMC Nephrol"},{"issue":"30","key":"798_CR28","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.3346\/jkms.2021.36.e218","volume":"36","author":"JH Lim","year":"2021","unstructured":"Lim JH, Han MH, Kim YJ, Kim MS, Jung HY, Choi JY, et al. New-onset nephrotic syndrome after Janssen COVID-19 vaccination: a case report and literature review. J Korean Med Sci. 2021;36(30):e218.","journal-title":"J Korean Med Sci"},{"issue":"4","key":"798_CR29","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1053\/j.ajkd.2021.06.008","volume":"78","author":"S Leclerc","year":"2021","unstructured":"Leclerc S, Royal V, Lamarche C, Laurin LP. Minimal change disease with severe acute kidney injury following the Oxford-AstraZeneca COVID-19 vaccine: a case report. Am J Kidney Dis. 2021;78(4):607\u201310.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"798_CR30","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1093\/ckj\/sfab153","volume":"15","author":"V Biradar","year":"2021","unstructured":"Biradar V, Konnur A, Gang S, Hegde U, Rajapurkar M, Patel H, et al. Adult-onset nephrotic syndrome following coronavirus disease vaccination. Clin Kidney J. 2021;15(1):168\u201370.","journal-title":"Clin Kidney J"},{"issue":"8","key":"798_CR31","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1016\/j.ekir.2021.06.024","volume":"6","author":"YJ Anupama","year":"2021","unstructured":"Anupama YJ, Patel RGN, Vankalakunti M. Nephrotic syndrome following ChAdOx1 nCoV-19 vaccine against SARScoV-2. Kidney Int Rep. 2021;6(8):2248.","journal-title":"Kidney Int Rep"},{"issue":"3","key":"798_CR32","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s13730-021-00673-z","volume":"11","author":"K Nagai","year":"2022","unstructured":"Nagai K, Kageyama M, Iwase M, Ueda A. A young adult with nephrotic syndrome following COVID-19 vaccination. CEN Case Rep. 2022;11(3):397\u20138.","journal-title":"CEN Case Rep"},{"key":"798_CR33","first-page":"662","volume":"118","author":"H Dormann","year":"2021","unstructured":"Dormann H, Kn\u00fcppel-Ruppert A, Amann K, Erley C. Nephrotic syndrome after vaccination against COVID-19: three new cases from Germany. Dtsch Arztebl Int. 2021;118:662\u20133.","journal-title":"Dtsch Arztebl Int"},{"issue":"3","key":"798_CR34","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1093\/ckj\/sfab234","volume":"15","author":"F Tanaka","year":"2021","unstructured":"Tanaka F, Katayama K, Joh K, Tsujimoto K, Yamawaki M, Saiki R, et al. Minimal change disease with thrombotic microangiopathy following the Pfizer-BioNTech COVID-19 vaccine. Clin Kidney J. 2021;15(3):567\u20138.","journal-title":"Clin Kidney J"},{"issue":"4","key":"798_CR35","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s13730-022-00702-5","volume":"11","author":"RI Mochizuki","year":"2022","unstructured":"Mochizuki RI, Takahashi N, Ikenouchi K, Shoda W, Kuyama T, Takahashi D. A de novo case of minimal change disease following the first dose of the Moderna mRNA-1273 SARS-CoV-2 vaccine without relapse after the second dose. CEN Case Rep. 2022;11(4):477\u201381.","journal-title":"CEN Case Rep"},{"issue":"1","key":"798_CR36","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000521981","volume":"12","author":"E Pella","year":"2022","unstructured":"Pella E, Sarafidis PA, Alexandrou ME, Stangou M, Nikolaidou C, Kosmidis D, et al. De novo minimal change disease in an adolescent after Pfizer-BioNTech COVID-19 vaccination: a case report. Case Rep Nephrol Dial. 2022;12(1):44\u20139.","journal-title":"Case Rep Nephrol Dial"},{"key":"798_CR37","unstructured":"WHO Coronavirus (COVID-19) Dashboard. https:\/\/covid19.who.int. Accessed 18 Mar 2023."},{"issue":"3","key":"798_CR38","first-page":"246","volume":"54","author":"JT Kielstein","year":"2000","unstructured":"Kielstein JT, Term\u00fchlen L, Sohn J, Kliem V. Minimal change nephrotic syndrome in a 65-year-old patient following influenza vaccination. Clin Nephrol. 2000;54(3):246\u20138.","journal-title":"Clin Nephrol"},{"issue":"2","key":"798_CR39","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.clineuro.2003.11.002","volume":"106","author":"CD Kao","year":"2004","unstructured":"Kao CD, Chen JT, Lin KP, Shan DE, Wu ZA, Liao KK. Guillain-barr\u00e9 syndrome coexisting with pericarditis or nephrotic syndrome after influenza vaccination. Clin Neurol Neurosurg. 2004;106(2):136\u20138.","journal-title":"Clin Neurol Neurosurg"},{"issue":"3","key":"798_CR40","first-page":"414","volume":"32","author":"S Guti\u00e9rrez","year":"2012","unstructured":"Guti\u00e9rrez S, Dotto B, Petiti JP, Paul AL, Dionisio de Cabalier ME, Torres AI, et al. Minimal change disease following influenza vaccination and acute renal failure: just a coincidence? Nefrologia. 2012;32(3):414\u20135.","journal-title":"Nefrologia"},{"issue":"5","key":"798_CR41","first-page":"349","volume":"43","author":"F Mac\u00e1rio","year":"1995","unstructured":"Mac\u00e1rio F, Freitas L, Correia J, Campos M, Marques A. Nephrotic syndrome after recombinant hepatitis B vaccine. Clin Nephrol. 1995;43(5):349.","journal-title":"Clin Nephrol"},{"issue":"2","key":"798_CR42","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2215\/CJN.05000516","volume":"12","author":"M Vivarelli","year":"2017","unstructured":"Vivarelli M, Massella L, Ruggiero B, Emma F. Minimal change disease. Clin J Am Soc Nephrol. 2017;12(2):332\u201345.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"798_CR43","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.semnephrol.2011.06.002","volume":"31","author":"T Ishimoto","year":"2011","unstructured":"Ishimoto T, Shimada M, Araya C, Huskey J, Garin E, Johnson R. Minimal change disease: a CD80 podocytopathy? Semin Nephrol. 2011;31(4):320\u20135.","journal-title":"Semin Nephrol"},{"issue":"7880","key":"798_CR44","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S0140-6736(74)91880-7","volume":"304","author":"RJ Shalhoub","year":"1974","unstructured":"Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet. 1974;304(7880):556\u201360.","journal-title":"Lancet"},{"issue":"7830","key":"798_CR45","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","volume":"586","author":"U Sahin","year":"2020","unstructured":"Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses. Nature. 2020;586(7830):594\u20139.","journal-title":"Nature"},{"issue":"11","key":"798_CR46","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.3390\/vaccines9111252","volume":"9","author":"HHL Wu","year":"2021","unstructured":"Wu HHL, Kalra PA, Chinnadurai R. New-onset and relapsed kidney histopathology following COVID-19 vaccination: a systematic review. Vaccines. 2021;9(11):1252.","journal-title":"Vaccines"},{"issue":"7872","key":"798_CR47","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41586-021-03791-x","volume":"596","author":"PS Arunachalam","year":"2021","unstructured":"Arunachalam PS, Scott MK, Hagan T, Li C, Feng Y, Wimmers F, et al. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature. 2021;596(7872):410\u20136.","journal-title":"Nature"},{"issue":"6","key":"798_CR48","doi-asserted-by":"publisher","first-page":"109504","DOI":"10.1016\/j.celrep.2021.109504","volume":"36","author":"C Bergamaschi","year":"2021","unstructured":"Bergamaschi C, Terpos E, Rosati M, Angel M, Bear J, Stellas D, et al. Systemic IL-15, IFN-\u03b3, and IP-10\/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Rep. 2021;36(6):109504.","journal-title":"Cell Rep"},{"key":"798_CR49","doi-asserted-by":"publisher","first-page":"103679","DOI":"10.1016\/j.ebiom.2021.103679","volume":"73","author":"F Massa","year":"2021","unstructured":"Massa F, Cremoni M, Gerard A, Grabsi H, Rogier L, Blois M, et al. Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients. EBioMedicine. 2021;73:103679.","journal-title":"EBioMedicine"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-023-00798-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-023-00798-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-023-00798-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T13:02:59Z","timestamp":1706792579000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-023-00798-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,27]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["798"],"URL":"https:\/\/doi.org\/10.1007\/s13730-023-00798-3","relation":{},"ISSN":["2192-4449"],"issn-type":[{"type":"electronic","value":"2192-4449"}],"subject":[],"published":{"date-parts":[[2023,5,27]]},"assertion":[{"value":"15 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors have declared no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights statement"}},{"value":"Informed consent was obtained from the patient for the publication of his clinical data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}